Cell Death and Disease · 2020 · 57 citations · 34 references
MedicineEndocrinologyPharmacologyCell SignalingRenal PathophysiologySignal TransductionGlomerular PathophysiologyHypertensive NephropathyRenal DiseaseRenal Molecular PhysiologyRenal PharmacologyRenal PhysiologyAldosterone SignalingHypertensive Glomerular DamageInduced HypertensionNadph Oxidase BiologyNadph Oxidase SignalingReactive Oxygen Species SignalingRenal Oxidative StressRenin-angiotensin-aldosterone System Activation
Abstract ELABELA (ELA), a 32-residue hormone peptide abundantly expressed in adult kidneys, has been identified as a novel endogenous ligand for APJ/Apelin receptor. The aim of this study was to investigate the role of ELA in deoxycorticosterone acetate (DOCA)/salt-induced hypertension and further explore the underlying mechanism. In DOCA/salt-treated rats, the mRNA level of ELA greatly decreased in the renal medulla. Next, overexpression of ELA in the kidney was found to attenuate DOCA/salt-induced hypertension and renal injury, including lower blood pressure, reversed glomerular morphological damage, decreased blood urea nitrogen (BUN), and blocked the accumulation of fibrotic markers. Mechanistically, ELA overexpression inhibited renal nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity and subsequent reactive oxygen species (ROS) production, thus resulted in the blockade of formation and activation of Nod-like receptor protein 3 (NLRP3) inflammasome. The inhibitory effects of ELA on Aldosterone-stimulated NADPH oxidase/ROS/NLRP3 inflammasome pathway were confirmed in the human renal tubular cells. Furthermore, our in vivo and in vitro results showed that the deficiency of the apelin receptor APJ did not influence the antihypertensive effect and blockage to NADPH oxidase/ROS/NLRP3 pathway of ELA. Moreover, in heterozygous ELA knockout mice (ELA +/− ), the ELA deficiency remarkably accelerated the onset of DOCA/salt-induced hypertension. Our data demonstrate that ELA prevents DOCA/salt-induced hypertension by inhibiting NADPH oxidase/ROS/NLRP3 pathway in the kidney, which is APJ independent. Pharmacological targeting of ELA may serve as a novel therapeutic strategy for the treatment of hypertensive kidney disease.
34
Toddler: An Embryonic Signal That Promotes Cell Movement via Apelin Receptors
Andrea Pauli, Megan L. Norris, Eivind Valen et al. · Science · 2014 · 630 citations
ELABELA: A Hormone Essential for Heart Development Signals via the Apelin Receptor
Serene C. Chng, Lena Ho, Jing Tian et al. · Developmental Cell · 2013 · 506 citations
Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy
Khurrum Shahzad, Fabian Bock, Wei Dong et al. · Kidney International · 2014 · 406 citations · Full text
Medicine, Nephrology, Pathobiology +17
Molecular Basis of Phosphorylation-Induced Activation of the NADPH Oxidase
Yvonne Groemping, Karine Lapouge, Stephen J. Smerdon et al. · Cell · 2003 · 394 citations · Full text